目的 探討百令膠囊聯(lián)合環(huán)磷酰胺和醋酸潑尼松治療腎病綜合征的臨床療效。方法 選取2015年3月—2016年3月在荊州市中心醫(yī)院接受治療的80例腎病綜合征患者，根據(jù)治療方案的差別分為對照組（40例）和治療組（40例）。兩組患者均給予降壓、利尿、降血脂等常規(guī)治療。對照組靜脈注射注射用環(huán)磷酰胺，10 mg/kg加入250 mL生理鹽水，1次/月；同時口服醋酸潑尼松片，起始劑量為40 mg/d，尿蛋白轉陰后維持劑量為10 mg/d。治療組在對照組基礎上口服百令膠囊，5粒/次，3次/d。兩組患者均連續(xù)治療2個月。觀察兩組的臨床療效，同時比較兩組治療前后血肌酐（Scr）、血尿素氮（BUN）、24 h尿蛋白排泄率（UPE）、總膽固醇（TC）、三酰甘油（TG）、低密度脂蛋白（LDL-C）、高密度脂蛋白（HDL-C）、白細胞介素-4（IL-4）、腫瘤壞死因子-α（TNF-α）、人11去氫血栓烷B2（11-DH-TXB2）和高遷移率族蛋白B1（HMGB1）的變化情況。結果 治療后，對照組和治療組總有效率分別為80.00%、95.00%，兩組比較差異有統(tǒng)計學意義（P<0.05）。治療后，兩組患者Scr、BUN、24 h UPE、TC、TG、LDL-C明顯降低，HDL-C顯著升高，同組治療前后差異有統(tǒng)計學意義（P<0.05），且治療組降低的更顯著（P<0.05）。治療后，兩組患者IL-4、TNF-α、11-DH-TXB2和HMGB1水平均較同組治療前降低，且治療組降低的更顯著（P<0.05）。結論 百令膠囊聯(lián)合環(huán)磷酰胺和醋酸潑尼松治療腎病綜合征療效顯著，可明顯改善患者腎功能，減輕炎性反應，具有一定的臨床應用推廣價值。

Objective To explore clinical efficacies of Corbrin Capsules combined with cyclophosphamide and prednisone acetate in treatment of nephrotic syndrome. Methods Patients (80 cases) with nephrotic syndrome in Jinzhou Central Hospital from March 2015 to March 2016 were divided into control group (40 cases) and treatment group (40 cases) according to the different treatments. All patients were given conventional basic treatment with anti-hypertension, diuresis, lipid lowering, etc. The patients in the control group were iv administered with Cyclophosphamide for injection, 10 mg/kg added into 250 mL normal saline, once a month; And they were po administered with Prednisone Acetate Tablets followed by an initial dose of 40 mg/d, then the maintenance dose was 10 mg/d after urinary protein turning negative. The patients in the treatment group were po administered with Corbrin Capsules on the basis of the control group, 5 grains/time, three times daily. The patients in two groups were treated for 2 months. After treatment, clinical efficacies were evaluated. And Scr, BUN, 24 h UPE, TC, TG, LDL-C, HDL-C, IL-4, TNF-α, 11-DH-TXB2, and HMGB1 in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 80.00% and 95.00%, respectively, and there were differences between two groups (P<0.05). After treatment, Scr, BUN, 24 h UPE, TC, TG, and LDL-C in two groups were obviously decreased (P<0.05), and HDL-C was significantly increased, and the difference was statistically significant in the same group (P<0.05). These changes of blood lipid levels in the treatment group were more significantly (P<0.05). After treatment, the levels of IL-4, TNF-α, 11-DH-TXB2, and HMGB1 in the two groups were significantly reduced (P<0.05), and these observational indexes in the treatment group were lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Corbrin Capsules combined with cyclophosphamide and prednisone acetate in treatment of nephrotic syndrome has a significant clinical efficacy, can improve the renal function, and relieve the inflammatory reaction, which has a certain clinical application value.